Press releases

Boston Scientific venous stent met VIRTUS trial primary effectiveness and safety endpoints in re-establishing blood flow.

Boston Scientific will webcast its conference call with financial results and business highlights for Q4 2018 and the full 2018 year.

Acquisition will expand structural heart portfolio to include transcatheter mitral annuloplasty repair system

Delaware court rules Edwards Lifesciences Infringes Boston Scientific patent

Transaction would expand Boston Scientific peripheral interventions portfolio with minimally invasive treatments for cancers and vascular conditions

"Through internal research and tuck-in acquisitions, we continue to bring meaningful innovations to market,” said CEO Mike Mahoney.

Court rules Edwards Lifesciences’ next-generation valve infringes Boston Scientific patent and grants right to enjoin sales in Germany.

The acquisition brings SpaceOAR, which decreases exposure to rectal radiation during prostate cancer radiotherapy, into the Boston Scientific portfolio.

Data support minimally invasive single-incision mesh procedure as a durable, safe and effective treatment for stress urinary incontinence.

Eluvia is the first peripheral vascular interventional technology approved in U.S. to offer a sustained release of a drug to treat peripheral artery disease.

First head-to-head trial assesses effectiveness of sustained drug release in interventional treatment for patients with blockages in femoropopliteal arteries.

New data at World Congress of Endourology demonstrate the Lithovue Empower device for kidney stone retrieval improves the OR experience.

Key data will include results from IMPERIAL trial evaluating ELUVIA drug-eluting stent and from REPRISE III study evaluating LOTUS Aortic Valve System.

Acquisition expands Boston Scientific portfolio of men's health in-office procedures with SpaceOAR, an adjunctive therapy for prostate cancer patients.

Acquisition will bolster Boston Scientific peripheral interventions portfolio with a treatment for venous obstructive disease

Boston Scientific acquisition adds the Sentinel® Cerebral Protection System, the only device cleared to protect patients against stroke risk in TAVR procedures.

"We're excited about the ways our differentiated pipeline will continue to drive our growth," said CEO Mike Mahoney.

Company does not endorse TRC's unsolicited mini-tender offer and recommends stockholders take no action.

Acquisition will add FDA-cleared Sentinel® Cerebral Embolic Protection System to expand Boston Scientific structural heart offerings.

Acquisition to expand Boston Scientific atrial fibrillation (Afib) ablation therapy offerings with innovative cryoballoon platform.

Data highlight the successful reduction of inappropriate shocks using the sensing filter in patients implanted with the EMBLEM™ S-ICD System.

Acquisition adds Rezūm®, a therapy for patients with symptomatic benign prostatic hyperplasia (BPH).

"Our consistently strong performance reflects our team's ongoing dedication,” said CEO Mike Mahoney.

Data demonstrated safety and effectiveness of VERCISE™ DBS System for controlling Parkinson’s symptoms.

European patent office revokes Edwards Lifesciences '550 patent.